170 Recruiting Advanced Solid Tumor Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Advanced Solid Tumor
Related Conditions
Top Recruiting Advanced Solid Tumor Studies
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
📍 State University of Iowa — Iowa City, Iowa
View Study & Checklist ➔A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
📍 California Clinical Trials Medical Group (CCTMG) — Glendale, California
View Study & Checklist ➔QTX3046 in Patients With KRAS G12D Mutations
📍 South Texas Accelerated Research Therapeutics, LLC Midwest — Grand Rapids, Michigan
View Study & Checklist ➔A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
📍 Providence St. Jude Medical Center — Fullerton, California
View Study & Checklist ➔A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
📍 NEXT Oncology — San Antonio, Texas
View Study & Checklist ➔First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
📍 Providence St. Jude Medical Center — Fullerton, California
View Study & Checklist ➔Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
📍 Local Institution - 2102 — La Jolla, California
View Study & Checklist ➔Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
📍 University of Iowa — Iowa City, Iowa
View Study & Checklist ➔A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
📍 City of Hope At Orange County Lennar Foundation Cancer Center — Irvine, California
View Study & Checklist ➔A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
📍 Northside Hospital — Marietta, Georgia
View Study & Checklist ➔Study of TTX-MC138 in Subjects With Advanced Solid Tumors
📍 Mary Crowley Cancer Center — Dallas, Texas
View Study & Checklist ➔M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
📍 NEXT Oncology - PARENT — New York, New York
View Study & Checklist ➔CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
📍 The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
📍 Moores Cancer Center, UCSD — La Jolla, California
View Study & Checklist ➔A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
📍 Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View Study & Checklist ➔Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
📍 Virginia Commonwealth University — Richmond, Virginia
View Study & Checklist ➔First in Human Study of TORL-3-600 in Participants With Advanced Cancer
📍 Providence Medical Foundation — Fullerton, California
View Study & Checklist ➔A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
📍 Research Site — Palo Alto, California
View Study & Checklist ➔Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
📍 Karmanos Cancer Center — Detroit, Michigan
View Study & Checklist ➔First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
📍 Site 139 — Bullhead City, Arizona
View Study & Checklist ➔Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
📍 Sarcoma Oncology Center — Santa Monica, California
View Study & Checklist ➔A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
📍 Ascendis Pharma Investigational Site — Los Angeles, California
View Study & Checklist ➔Study of CHS-114 in Participants With Advanced Solid Tumors
📍 Stanford Cancer Center — Palo Alto, California
View Study & Checklist ➔A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
📍 Florida Cancer Specialists — Sarasota, Florida
View Study & Checklist ➔A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
📍 Carolina BioOncology Institute — Huntersville, North Carolina
View Study & Checklist ➔Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
📍 START Midwest — Grand Rapids, Michigan
View Study & Checklist ➔A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
📍 Mayo Clinic — Scottsdale, Arizona
View Study & Checklist ➔Study of LP-184 in Patients With Advanced Solid Tumors
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
📍 Columbia University Medical Center — New York, New York
View Study & Checklist ➔A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
📍 Duke Cancer Institute — Durham, North Carolina
View Study & Checklist ➔Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors
📍 IntraAb Inc. — Richmond, California
View Study & Checklist ➔Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
📍 NEXT Oncology — San Antonio, Texas
View Study & Checklist ➔Study in Advanced Solid Tumor Patients
📍 DFCI — Boston, Massachusetts
View Study & Checklist ➔Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
📍 University of California San Diego — La Jolla, California
View Study & Checklist ➔JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
📍 California Cancer Associates for Research and Excellence — Encinitas, California
View Study & Checklist ➔A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
📍 Usc Norris Comprehensive Cancer Center (Nccc) — Los Angeles, California
View Study & Checklist ➔A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔A Study of YL242 in Subjects With Advanced Solid Tumors
📍 US-201 — New Haven, Connecticut
View Study & Checklist ➔